With questions already swirling about the actual affordability impact of the government’s drug purchasing portal TrumpRx, the White House is updating the platform to address a key gap in the medicines ...
President Donald Trump earlier this year bought as much as $680,000 in stock of Eli Lilly, the maker of blockbuster obesity ...
Roche has signed a voluntary license agreement providing its popular influenza antiviral drug Xofluza (baloxavir marboxil) ...
As Eli Lilly moves to set up a mammoth manufacturing facility in Houston, it’s not the only U.S. pharma juggernaut with an ...
A Novartis cross-border partnership is turning into a standoff. | A Novartis cross-border partnership is turning into a ...
Even as a new drug pricing specter rears its head in President Donald Trump’s “Most Favored Nation” policies, drugmakers ...
Over the last 18 months, Merck and Kelun-Biotech have notched four approvals in China for their TROP2-directed antibody-drug ...
Eli Lilly has partnered with basketball star Caitlin Clark’s foundation to open three multisport community courts across ...
Already tracking at $5 billion in annual sales, Enhertu has secured two new FDA approvals to treat early breast cancer. But ...
As President Donald Trump lands in Beijing, one major industry is missing from his business delegation—pharma. | As President ...
After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor ...
With the ink barely dry on outgoing commissioner Marty Makary’s resignation, another top regulator may be heading for the exit at the FDA. | With the ink barely dry on outgoing commissioner Marty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results